TB-500
Also known as Thymosin Beta-4 Acetate
Studied for: recovery research
TB-500 is a synthetic fragment of thymosin beta-4. Research focuses on its relationship with actin, the structural protein underpinning cell movement, and with the migration of repair cells.
Last reviewed September 26, 2026
How it is thought to work
Research describes TB-500 as binding actin monomers and influencing the assembly of the cytoskeleton, which is central to how cells move toward a site of tissue stress.
- Actin RegulationStudied for sequestering actin monomers, affecting the cytoskeletal scaffolding cells use to move and reorganize.
- Cell MigrationExplored for the recruitment of repair-associated cells toward areas under stress.
- Route studied
- Subcutaneous
- Research status
- Preclinical
Published work on TB-500 itself is largely animal research, such as rat tendon-healing studies, while its parent protein, thymosin beta-4, has been discussed more broadly in reviews of regenerative and clinical applications.
Research
What the research covers
What research examines
- Actin monomer binding and cytoskeletal organization
- Migration of repair-associated cells
- Achilles tendon healing in rat models
- Musculoskeletal injury in peptide therapy reviews
- Thymosin beta-4 in brain organoid research
Reported effects in studies
- Human safety data are limited
- Adverse events are not summarized in the cited animal studies
- Discussed among unapproved peptides in a review of safety and efficacy for musculoskeletal injuries
- Supplied for laboratory research use only
Studied range
What research protocols have used
Research protocols have used 500–2,000 mcg per administration, once weekly (morning), with a loading phase before a lower-frequency maintenance phase, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- BPC-157BPC-157 is a synthetic sequence derived from a protein found in gastric juice. Research examines its role in gut barrier integrity, connective-tissue repair, and the signaling that coordinates healing.Read profile$49
- GHK-CuGHK-Cu is a copper-binding tripeptide studied for its role in skin, connective-tissue, and cellular renewal. Its recovery profile gives it a crossover into Foundation.Read profile$39
- KPVKPV is the C-terminal tripeptide fragment of alpha-MSH. Research examines its anti-inflammatory profile, particularly within the gut, and its activity independent of pigmentation signaling.Read profile$69
- CJC-1295CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.Read profile$119
Studies
Cited research
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Joint diseases and related surgery · 2026 · PMID 42542926
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Expert opinion on biological therapy · 2012 · PMID 22074294
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026 · Review · PMID 41966639
- beta-Thymosins.
Annals of the New York Academy of Sciences · 2007 · Review · PMID 17468232
- Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids.
Stem cell reports · 2025 · PMID 40816274
FAQ
Questions about TB-500
TB-500, also known as Thymosin Beta-4 Acetate, is a synthetic fragment of thymosin beta-4, a naturally occurring peptide in the beta-thymosin family. Research interest centers on its relationship with actin, the structural protein that underpins cell movement, and on the migration of repair-associated cells. It is typically grouped with recovery-focused research compounds and is supplied for laboratory research use only.
Research describes TB-500 as binding actin monomers and influencing assembly of the cytoskeleton, the internal scaffolding cells use to move and reorganize. By sequestering actin monomers, it is studied for effects on how cells migrate toward sites of tissue stress. A related line of research explores its role in recruiting repair-associated cells to stressed areas. These mechanisms are drawn largely from laboratory and animal work rather than controlled human trials.
Studies have examined TB-500 and its parent protein, thymosin beta-4, in several regenerative contexts. A rat study assessed Achilles tendon healing using histopathological and biomechanical measures. Reviews have discussed thymosin beta-4 as a multi-functional regenerative peptide, and a recent review covered unapproved peptides studied for musculoskeletal injuries and athletic performance. Thymosin beta-4 has also been investigated as a target in human brain organoid models of Alzheimer disease. Evidence remains early.
Human safety data for TB-500 are limited. The animal studies focus on tissue and mechanical outcomes, and adverse events are not summarized in them. A 2026 review in Sports Medicine discussed the safety and efficacy of approved and unapproved peptides for musculoskeletal injuries, placing compounds like TB-500 within the unapproved category. TB-500 is not an approved therapeutic and is supplied only for laboratory research.
Research protocols have used 500 to 2,000 mcg per administration by the subcutaneous route, once weekly in the morning, with a loading phase before a lower-frequency maintenance phase. These protocols have run in 8-week blocks followed by 4 weeks off. Each CoreX order ships with a protocol guide describing these research parameters. This information describes published research practice only.
Ask about TB-500
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- BPC-157 vs TB-500BPC-157 is a synthetic sequence derived from a protein found in gastric juice, while TB-500 is a synthetic fragment of thymosin beta-4. Their studied mechanisms differ. Research on BPC-157 centers on angiogenic signaling, including VEGF-associated pathways, and on the integrity of the intestinal lining. TB-500 is described as binding actin monomers and influencing the cytoskeletal assembly involved in cell migration. BPC-157 has been studied for musculoskeletal soft tissue healing, wound healing and gastroprotection, and one small human report examined knee pain. TB-500 has been studied mainly in animal models, such as rat Achilles tendon healing. For both compounds, human safety data are limited.